ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Obesity, type 2 diabetes, and testosterone in aging men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 228098" data-attributes="member: 13851"><p><strong>Obesity, type 2 diabetes, and testosterone in ageing men (2022)</strong></p><p><em>Gary Wittert · Mathis Grossmann</em></p><p></p><p></p><p><strong>Abstract</strong></p><p></p><p><em>In the absence of obesity, adverse lifestyle behaviours, and use of medication such as opioids serum testosterone concentrations decrease by only a minimal amount at least until very advanced age in most men. <strong>Obesity is heterogeneous in its phenotype, and it is the accumulation of excess adipose tissue viscerally associated with insulin resistance, dyslipidaemia, inflammation, hypothalamic leptin resistance and gliosis that underpins the functional hypogonadism of obesity. Both central (hypothalamic) and peripheral mechanisms are involved resulting in a low serum total testosterone concentration, while LH and FSH are typically in the normal range. Peripherally a decrease in serum sex hormone binding globulin (SHBG) concentration only partially explains the decrease in testosterone and there is increasing evidence for direct effects in the testis. </strong>Men with obesity-associated functional hypogonadism and serum testosterone concentrations below 16 nmol/L are at increased risk of incident type 2 diabetes (T2D); high testosterone concentrations are protective. The magnitude of weight loss is linearly associated with an increase in serum testosterone concentration and with the likelihood of preventing T2D or reverting newly diagnosed disease; treatment with testosterone for 2 years increases the probability of a positive outcome from a lifestyle intervention alone by approximately 40%. Whether the additional favourable benefits of testosterone treatment on muscle mass and strength and bone density and quality in the long-term remains to be determined.</em></p><p></p><p></p><p></p><p></p><p><strong>1 Ageing and the hypothalamic-pituitary-testicular (HPT) axis</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>2 Obesity and obesity-related chronic disorders and the HPT axis</strong></p><p><strong></strong></p><p><strong>2.1 Obesity</strong></p><p><strong></strong></p><p><strong>2.2 Obesity-related chronic disorders</strong></p><p><strong></strong></p><p><strong>2.3 Health-related behaviours</strong></p><p><strong></strong></p><p><strong>2.4 Medications</strong></p><p><strong></strong></p><p><strong>2.5 Macronutrient intake</strong></p><p><strong></strong></p><p><strong>2.6 Mechanisms of obesity-related HPT axis dysregulation</strong></p><p><em>2.6.1 Central mechanisms</em></p><p><em>2.6.2 Peripheral mechanisms</em></p><p></p><p></p><p><strong>3 Clinical implications </strong></p><p><strong></strong></p><p><strong>3.1 Serum testosterone and type 2 diabetes risk</strong></p><p><strong></strong></p><p><strong>3.2 Effect of weight loss on obesity-associated functional hypogonadism</strong></p><p><strong></strong></p><p><strong>3.3 Is there a role for treatment with testosterone?</strong></p><p><strong></strong></p><p><strong>3.4 Mechanism of the effect of testosterone on glucose metabolism</strong></p><p><strong></strong></p><p><strong>3.5 Implications for practice</strong></p><p></p><p>● <em>Low serum testosterone concentrations with increasing age are predominantly the consequence of obesity-associated chronic disease, opioid use, and modifiable health-related behaviours.</em></p><p></p><p>● <em>The aim of clinical assessment must be to exclude the presence of pathological hypogonadism, identify and effectively manage co-morbid physical and psychological chronic conditions and provide education and support to optimise health-related behaviours. Such measures have been shown to treat or prevent chronic disease, increase serum testosterone concentration, and improve sexual function.</em></p><p></p><p>●<em> Treatment with testosterone in combination with a lifestyle program in centrally obese men with impaired glucose tolerance or newly diagnosed T2D can decrease fat mass, improve glucose tolerance, and prevent or reverse recently diagnosed type 2 diabetes. </em></p><p></p><p>● <em>The durability of benefit and longer-term safety of testosterone used as a pharmacological approach for T2D prevention in men with obesity-associated functional hypogonadism, and whether there are subgroups of men who will benefit, remain to be determined.</em></p><p></p><p>● <em>It is not known whether the testosterone-induced increase in bone and skeletal muscle mass and grip strength will reduce the risks of subsequent fracture or frailty.</em></p></blockquote><p></p>
[QUOTE="madman, post: 228098, member: 13851"] [B]Obesity, type 2 diabetes, and testosterone in ageing men (2022)[/B] [I]Gary Wittert · Mathis Grossmann[/I] [B]Abstract[/B] [I]In the absence of obesity, adverse lifestyle behaviours, and use of medication such as opioids serum testosterone concentrations decrease by only a minimal amount at least until very advanced age in most men. [B]Obesity is heterogeneous in its phenotype, and it is the accumulation of excess adipose tissue viscerally associated with insulin resistance, dyslipidaemia, inflammation, hypothalamic leptin resistance and gliosis that underpins the functional hypogonadism of obesity. Both central (hypothalamic) and peripheral mechanisms are involved resulting in a low serum total testosterone concentration, while LH and FSH are typically in the normal range. Peripherally a decrease in serum sex hormone binding globulin (SHBG) concentration only partially explains the decrease in testosterone and there is increasing evidence for direct effects in the testis. [/B]Men with obesity-associated functional hypogonadism and serum testosterone concentrations below 16 nmol/L are at increased risk of incident type 2 diabetes (T2D); high testosterone concentrations are protective. The magnitude of weight loss is linearly associated with an increase in serum testosterone concentration and with the likelihood of preventing T2D or reverting newly diagnosed disease; treatment with testosterone for 2 years increases the probability of a positive outcome from a lifestyle intervention alone by approximately 40%. Whether the additional favourable benefits of testosterone treatment on muscle mass and strength and bone density and quality in the long-term remains to be determined.[/I] [B]1 Ageing and the hypothalamic-pituitary-testicular (HPT) axis 2 Obesity and obesity-related chronic disorders and the HPT axis 2.1 Obesity 2.2 Obesity-related chronic disorders 2.3 Health-related behaviours 2.4 Medications 2.5 Macronutrient intake 2.6 Mechanisms of obesity-related HPT axis dysregulation[/B] [I]2.6.1 Central mechanisms 2.6.2 Peripheral mechanisms[/I] [B]3 Clinical implications 3.1 Serum testosterone and type 2 diabetes risk 3.2 Effect of weight loss on obesity-associated functional hypogonadism 3.3 Is there a role for treatment with testosterone? 3.4 Mechanism of the effect of testosterone on glucose metabolism 3.5 Implications for practice[/B] ● [I]Low serum testosterone concentrations with increasing age are predominantly the consequence of obesity-associated chronic disease, opioid use, and modifiable health-related behaviours.[/I] ● [I]The aim of clinical assessment must be to exclude the presence of pathological hypogonadism, identify and effectively manage co-morbid physical and psychological chronic conditions and provide education and support to optimise health-related behaviours. Such measures have been shown to treat or prevent chronic disease, increase serum testosterone concentration, and improve sexual function.[/I] ●[I] Treatment with testosterone in combination with a lifestyle program in centrally obese men with impaired glucose tolerance or newly diagnosed T2D can decrease fat mass, improve glucose tolerance, and prevent or reverse recently diagnosed type 2 diabetes. [/I] ● [I]The durability of benefit and longer-term safety of testosterone used as a pharmacological approach for T2D prevention in men with obesity-associated functional hypogonadism, and whether there are subgroups of men who will benefit, remain to be determined.[/I] ● [I]It is not known whether the testosterone-induced increase in bone and skeletal muscle mass and grip strength will reduce the risks of subsequent fracture or frailty.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Obesity, type 2 diabetes, and testosterone in aging men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top